Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783835 | 0.92 | HTT (0.53) | HTTL3MBTL1POLBHDAC6TDP1 | |
| SCHEMBL2351821 | 0.86 | HTT (0.57) | HTTL3MBTL1POLBHDAC6TDP1 | |
| SCHEMBL2350429 | 0.85 | HTT (0.56) | HTTL3MBTL1POLBHDAC6TDP1 | |
| Hydrochloric Acid SCHEMBL2348443 | 0.84 | HTT (0.55) | HTTL3MBTL1POLBHDAC6TDP1 | |
| SCHEMBL13373334 | 0.83 | L3MBTL1 (0.64) | HTTL3MBTL1POLBHDAC6TDP1 | |
| SCHEMBL2353678 | 0.83 | HTT (0.57) | HTTL3MBTL1POLBHDAC6TDP1 | |
| SCHEMBL13373316 | 0.83 | HTT (0.57) | HTTL3MBTL1POLBHDAC6TDP1 | |
| SCHEMBL2352590 | 0.83 | HTT (0.54) | HTTL3MBTL1POLBHDAC6TDP1 | |
| SCHEMBL2355361 | 0.82 | HTT (0.55) | HTTL3MBTL1POLBHDAC6TDP1 | |
| SCHEMBL2352195 | 0.82 | HTT (0.56) | HTTL3MBTL1POLBHDAC6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | THE PROCTER & GAMBLE COMPANY | 2004-01-08 | — | — | US | disclosed |
| WO-2002016327-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS NEUTROPHIL INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | MPO, SERPINB1, NCF1 | HTT 4172/4885L3MBTL1 4198/4885POLB 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.